MedImmune, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of products for prevention and treatment in therapeutic areas of infectious diseases, inflammatory diseases, and cancer in the United States. The company markets three products: Synagis, a humanized monoclonal antibody for the prevention of lower respiratory tract disease caused by respiratory syncytial virus in pediatric patients; Ethyol for the treatment of unwanted side effects of specific types of chemotherapies and radiotherapies that are used to treat cancer; and FluMist, a vaccine for the prevention of disease caused by influenza A and B viruses in healthy children and adolescents. The company also provides NeuTrexin, a trimetrexate glucuronate for injection; and RespiGam. In addition, MedImmune has various products under development stages. The company’s customers include pharmaceutical wholesalers, distributors, and specialty distributors. MedImmune, Inc. has strategic alliances with Critical Therapeutics, Inc. and Micromet AG. The company was founded in 1987 under the name Molecular Vaccines, Inc. and changed its name to MedImmune, Inc. in 1990. MedImmune is headquartered in Gaithersburg, Maryland. As of June 5, 2007, MedImmune Inc. is a subsidiary of AstraZeneca PLC.
| 
